The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice

Vaccine

Volumn 29, Issue 25, 2011, Pages 4256-4263

  Bernardo, Lidice ^a   Pavón, Alequis ^a   Hermida, Lisset ^b   Gil, Lázaro ^b   Valdés, Iris ^b   Cabezas, Sheila ^a   Linares, Ramón ^a   Alvarez, Mayling ^a   Silva, Ricardo ^b   Guillén, Gerardo ^b   Nagy, Eszter ^c   Schlick, Petra ^c   Guzmán, María G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c INTERCELL AG   (Austria)

Author keywords

Dengue; Domain III; IC31 adjuvant

Indexed keywords

GAMMA INTERFERON; HYBRID PROTEIN; IC31; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; PROTEIN PD5; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE VIRUS 2; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG COMBINATIONS; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; VIRAL ENVELOPE PROTEINS;

EID: 79956220690     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.040     Document Type: Article

References (48)

1. Burke D.S., Monath T.P. Flaviviruses fields virology 2001, 1043-1125. Lippincott Williams & Wilkins, London, New York, Tokyo. D.M. Knippe, P.M. Howley (Eds.).
2. WHO. Dengue Impact. 2008 [cited 2009 November 21]; Available from: http://www.who.int/csr/disease/dengue/impact/en/index.html.
3. Guzman M.G., Perez A.B., Fuentes O., Kouri G. Dengue, dengue hemorrhagic fever 2008, International Encyclopedia of Public Health, p. 98-119.
4. Guy B., Almond J.W. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008, 31(March (2-3)):239-252.
5. Roehrig J.T., Volpe K.E., Squires J., Hunt A.R., Davis B.S., Chang G.J. Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol 2004, 78(March (5)):2648-2652.
6. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillen G. Domain III of the envelope protein as a dengue vaccine target. Exp Rev Vaccines 2010, 9(1):87-97.
7. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75(August (16)):7769-7773.
8. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246(July (2)):317-328.
9. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992, 187(April (2)):480-491.
10. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998, 58(May (5)):655-662.
11. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65(August (2)):159-161.
12. Izquierdo A., Bernardo L., Martin J., Santana E., Hermida L., Guillen G., et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 2008, 138(1-2):135-138.
13. Zulueta A., Hermida L., Lazo L., Valdes I., Rodriguez R., Lopez C., et al. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 2003, 308(August (3)):619-626.
14. Zulueta A., Martin J., Hermida L., Alvarez M., Valdes I., Prado I., et al. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 2006, 121(October (1)):65-73.
15. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., López C., et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008, 80(November (2)):194-199.
16. Pulendran B. Modulating vaccine responses with dendritic cells and toll-like receptors. Immunol Rev 2004, 199:227-250.
17. Kritsch C., Berger A., Heinrich-Cseh C., Bujajska-Schretter A., Zauner W. Separation and quantification of a novel two-component adjuvant. J Chromatogr B: Analyt Technol Biomed Life Sci 2005, 822(1-2):263-270.
18. Fritz J.H., Brunner S., Birnstiel M.L., Buschle M., Gabain A., Mattner F., et al. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type response to co-injected antigens. Vaccine 2004, 22(25-26):3274-3284.
19. ® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 2008, 26:3461-3468.
20. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24(June (26)):5461-5472.
21. Lingnau K., Riedl K., von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007, 6(5):741-746.
22. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006, 24(26):5452-5460.
23. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008, 3(11):e3683.
24. Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol 2009, 69(3):194-202.
25. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 2009, 4(6):e5930.
26. van Diesel J., Arend S.M., Prins C., Bang P., Nyholm-Tingskov T., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
27. Clarke D.H., Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958, 7:561-573.
28. Kouri G., Mas P., Guzman M.G., Soler M., Goyenechea A., Morier L. Dengue hemorrhagic fever in Cuba 1981 rapid diagnosis of the etiologic agent. Bull Pan Am Health Organ 1983, 17(2):126-132.
29. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, (May).
30. Lopez C., Sanchez J., Hermida L., Zulueta A., Marquez G. Cysteine mediated multimerization of a recombinant dengue E fragment fused to the P64k protein following immobilized metal ion affinity chromatography. Protein Expr Purif 2004, 34(April (2)):176-182.
31. Morens D.M., Halstead S.B., Repik P.M., Putvatana R., Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985, 22(August (2)):250-254.
32. Alvarez M., Rodriguez-Roche R., Bernardo L., Morier L., Guzman G. Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 2005, 29:1-9.
33. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5):488-496.
34. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D., et al. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 1999, 17(March (11-12)):1312-1320.
35. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(August (35)):4442-4452.
36. Guzman M.G., Rodriguez R., Hermida L., Alvarez M., Lazo L., Mune M., et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003, 69(August (2)):129-134.
37. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80(October (19)):9577-9585.
38. Khanam S., Etemad B., Khanna N., Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 2006, 74(February (2)):266-277.
39. Kamath A.T., Valenti M.P., Rochat A.F., Agger E.M., Lingnau K., von Gabain A., et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 2008, 38(5):1247-1256.
40. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004, 78(March (6)):2701-2710.
41. Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009, 182(8):4865-4873.
42. Laoprasopwattana K., Libraty D.H., Endy T.P., Nisalak A., Chunsuttiwat S., Ennis F.A., et al. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J Infect Dis 2007, 195(April (8)):1108-1116.
43. Yamanaka A., Kosugi S., Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 2008, 82(January (2)):927-937.
44. Rozsnyay Z., Sarmay G., Walker M. Distinctive role of IgG1 and IgG3 isotypes in Fc gamma R-mediated functions. Immunology 1989, 66:491-498.
45. Halstead S.B., Antibody macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis Suppl 1989, May-June (4):S830-S839.
46. Gil L., López C., Blanco A., Lazo L., Martín J., Valdés I., et al. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009, 22(1):23-30.
47. Lazo L., Hermida L., Zulueta A., Sanchez J., Lopez C., Silva R., et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 2007, 25(January (6)):1064-1070.
48. van Der Most R.G., Murali-Krishna K., Ahmed R., Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 2000, 74(September (17)):8094-8101.